We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Medtronic to Build Insulin Pump Manufacturing Facility in China

By HospiMedica International staff writers
Posted on 17 Jan 2016
Medtronic (Dublin, Ireland) has formed a partnership with the Chengdu municipal government (China) to manufacture and deploy advanced diabetes therapies in the city. More...


As part of the agreement, Medtronic will invest in a manufacturing facility for a next generation sensor augmented pump system with SmartGuard technology that will help provide better treatment management for the growing diabetes population in China. In addition, Medtronic will partner with the Chengdu government to enable habitants of the metropolitan area and the broader Sichuan province to access the locally produced technology, with software displayed in Chinese language.

The manufacturing facility is the second Medtronic plant to be built in Chengdu, following a previous announcement in August 2014 that stated the company would establish its first factory worldwide for portable hemodialysis equipment in in the city. Following that agreement, Medtronic and the Chengdu municipality signed a strategic partnership agreement in September 2015, with the intention of expanding access in China and other countries to proven solutions for the management of diabetes and other diseases.

“Medtronic and Chengdu share a commitment to transform diabetes care through advanced therapies that can provide greater freedom and better health to over one hundred million people living with diabetes in China,” said Alejandro Galindo, president of the intensive insulin management business at Medtronic. “By manufacturing both advanced insulin pumps and hemodialysis products in Chengdu, we will benefit from the expertise of this global medical technology hub, while expanding access of our innovative therapies to China's growing population.”

“The latest agreement marks another milestone in collaboration between Chengdu and Medtronic and confirms the potential of a public private partnership to improve health and quality of life for underserved diabetes population in China and beyond,” said Yuan Zongyong, deputy director of the Chengdu High Tech Zone.

Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals, and patients in approximately 160 countries, and prefers collaborating with stakeholders in each country in which it operates. The Chinese government, on its part, is known to favor devices made locally through by promoting policies such as favorable reimbursement, giving them an edge over imported products.

Related Links:

Medtronic
Chengdu municipal government



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Adhesive
MED 5570U
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie MellonImage: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie Mellon University)University)

Portable Artificial Lung Technology Could Reshape Care for Chronic Lung Disease

Chronic lung disease can leave patients dependent on prolonged mechanical ventilation or awaiting transplantation, both of which carry substantial morbidity and healthcare costs. Ventilatory support may... Read more

Surgical Techniques

view channel
Image Credit: 123RF

Needle-Free Intrauterine Anesthesia Technique Reduces Pain During IUD Insertion

Pain during intrauterine device (IUD) placement often deters women from choosing this long-acting contraception. Avoiding or undertreating procedural pain can reduce uptake and satisfaction with effective... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.